ClinicalTrials.gg
CompletedNCT02415400Updated Jun 11, 2020Results posted

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

A Phase 4 interventional study of Apixaban and vitamin K antagonist in Acute Coronary Syndromes, sponsored by Bristol-Myers Squibb. Completed at 626 sites in 37 countries. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2020-06-11.

Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
4,614
Allocation
Randomized
Ages
18 Years to 95 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 265 studies in Acute Coronary Syndrome with a site in United States — 14 open to participants now, 21 under way, 2 of them phase 3. Acute Coronary Syndrome · United States.

Enrollment
28th of 186
4,614 · median 150
Started
2015
with 8 others
Phase 4
27 of 265
none open now
Registered
161st of 265
by date

Among the 265 studies in Acute Coronary Syndrome with a site in United States, this one is the 28th largest by enrollment of the 186 interventional ones that give a count, is one of 9 that started in 2015, is one of 27 in phase 4, and was the 161st registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

14 of the 265 studies in Acute Coronary Syndrome with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 95 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Acute Coronary Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine if Apixaban is safer than a Vitamin K Antagonist given for 6 months in terms of bleeding in patients with an irregular heart beat (atrial fibrillation) and a recent heart attack or a recent procedure to open up a blood vessel in the heart. All patients would also be taking a class of medicines called P2Y12 inhibitors (such as clopidogrel/Plavix) and be treated for up to 6 months. The primary focus will be a comparison of the bleeding risk of Apixaban, with or without aspirin, versus a Vitamin K antagonist, such as warfarin, with or without aspirin.

Read the detailed description

Patients will be recruited from either inpatient coronary care or general medical units, or recruited from outpatient cardiology offices.

Masking:

Apixaban: Open label.

VKA: Open label.

Acetylsalicylic acid film coated tablet: Double Blinded.

Placebo matching Acetylsalicylic acid film coated tablet: Double Blinded.

03

Conditions studied

  • Acute Coronary Syndromes
04

Who can participate

Ages eligible
18 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Adults with either active or a history of non-valvular atrial fibrillation or flutter with the planned or existing use of an oral anticoagulant for prophylaxis of thromboembolism. In addition, subjects must have had an acute coronary syndrome or percutaneous coronary intervention with a stent within the prior 14 days
  • Planned use of antiplatelet agents for at least 1 to 6 months
  • Males and Females ≥ 18 years of age
  • Women of must have a negative serum or urine pregnancy test within 24 hours prior to the start of study drug

Exclusion criteria

Exclusion Criteria:

  • Conditions other than atrial fibrillation that require chronic anticoagulation. (e.g. prosthetic mechanical heart valve)
  • Severe renal insufficiency (serum creatinine > 2.5 mg/dL or a calculated \< 30 mL/min
  • Patients with a history of intracranial hemorrhage
  • Patients have had or will undergo Coronary arterial bypass graft (CABG) for their index acute coronary syndrome (ACS) event
  • Patients with known ongoing bleeding and patients with known coagulopathies
  • Any or allergies to VKA, apixaban, or to intended P2Y12 antagonists or to aspirin
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
4,614 participants (actual)

Study arms

  • Active comparator
    Apixaban

    5 mg or 2.5 mg Apixaban tablets orally twice per day

    Drug: Apixaban

  • Active comparator
    Vitamin K Antagonist

    VKA tablets orally once daily

    Drug: vitamin K antagonist

  • Placebo comparator
    Acetylsalicylic acid film coated tablet

    81 mg Acetylsalicylic acid film coated tablet orally once daily

    Drug: Acetylsalicylic acid

  • Placebo comparator
    Placebo matching Acetylsalicylic acid film coated tablet

    Placebo matching Acetylsalicylic acid film coated tablet once daily

    Other: Acetylsalicylic acid placebo

Interventions

  • Also known as: BMS-562247

  • DrugAcetylsalicylic acid

    Also known as: Aspirin 81 mg

  • OtherAcetylsalicylic acid placebo

    Also known as: aspirin placebo

06

What researchers measure

Primary outcomes

  1. The Rate of International Society on Thrombosis and Haemostasis (ISTH) Major or Clinically Relevant Non-Major (CRNM) Bleeding With Apixaban Versus Vitamin K Antagonist (VKA) During the Treatment Period

    Time to first ISTH major or CRNM bleeding during the 6-month period of treatment with Apixaban or VKA. N is the number of participants treated with Apixaban or VKA. n is the number of participants treated with Apixaban or VKA with major or CRNM bleeding in each treatment group during the 6-month period of treatment. Event rates are calculated based on the number of participants with major or CRNM bleeding divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year.

    Time frame: Approximately 6 months

  2. The Rate of ISTH Major or CRNM Bleeding With Aspirin Versus no Aspirin During the Treatment Period

    Time to first ISTH major or CRNM bleeding during the treatment period of 6 months with aspirin or placebo. N is the number of participants with aspirin or placebo. n is the number of participants treated with aspirin or placebo with major or CRNM bleeding in each treatment group during the 6-month period of treatment. Event rates are calculated based on the number of participants with event of interest divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year.

    Time frame: Approximately 6 months

Secondary outcomes

  1. Superiority on ISTH Major or CRNM Bleeding for Apixaban Versus VKA

    Time to first occurrence during the time the participants were treated with Apixaban or VKA. N is the number of participants treated with Apixaban or VKA. n is the number of participants treated with Apixaban or VKA with major or CRNM bleeding in each treatment group during the 6-month period of treatment. Event rates are calculated based on the number of participants with event of interest divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year.

    Time frame: Approximately 6 months

  2. The Rate of All-cause Death or All-cause Rehospitalization With Apixaban Versus VKA

    Time to first all-cause death or all-cause hospitalization during the during the 6-month treatment period with Apixaban or VKA. N is the number of participants treated with Apixaban or VKA. n is the number of participants treated with Apixaban or VKA with all-cause death or all-cause hospitalization in each treatment group during the 6-month period of treatment. Event rates are calculated based on the number of participants with all-cause death or all-cause hospitalization divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year.

    Time frame: Approximately 6 months

  3. The Rate of All-cause Death or All-cause Rehospitalization With Aspirn Versus no Aspirin

    Time to first all-cause death or all-cause hospitalization during the 6-month period of treatment with aspirin or placebo. N is the number of participants treated with aspirin or placebo. n is the number of participants treated with aspirin or placebo with all-cause death or all-cause hospitalization in each treatment group during the 6-month period of treatment. Event rates are calculated based on the number of participants with all-cause death or all-cause hospitalization divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year.

    Time frame: Approximately 6 months

  4. The Rate of the Composite Endpoint of Death or Ischemic Events (Stroke, Myocardial Infarction, Stent Thrombosis, Urgent Revascularization) With Apixaban Versus VKA

    Time to first occurrence during the 6-month treatment period with Apixaban or VKA. N is the number of participants treated with Apixaban or VKA. n is the number of participants treated with Apixaban or VKA with death or ischemic events in each treatment group during the during the 6-month period of treatment. Event rates are calculated based on the number of participants with death or ischemic events divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year.

    Time frame: Approximately 6 months

  5. The Composite Endpoints of Death and Ischemic Events (Stroke, Myocardial Infarction, Stent Thrombosis, Urgent Revascularization) With Aspirin Versus no Aspirin

    Time to first death or ischenic event during the 6-month treatment period with aspirin or placebo. N is the number of participants treated with aspirin or placebo. n is the number of participants treated with aspirin or placebo with death or ischemic events in each treatment group during the 6-month treatment period. Event rates are calculated based on the number of participants with death or ischemic events divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year.

    Time frame: Approximately 6 months

07

Results

Posted Feb 7, 2020

Participant flow

Participant flow — Overall Study
MilestoneApixaban With Acetylsalicylic Acid Film Coated TabletApixaban With Placebo Matching Acetylsalicylic AcidVitamin K Antagonist (VKA) With Acetylsalicylic AcidVKA With Placebo Matching Acetylsalicylic Acid
Started1153115311541154
Completed1087109110691071
Not completed66628583
Withdrew: Adverse event0112
Withdrew: Participant request to stop therapy4386
Withdrew: Participant withdrew consent14123021
Withdrew: Death39413542
Withdrew: Lost to follow-up3325
Withdrew: Poor/non-compliance0134
Withdrew: Participant no longer meets criteria2001
Withdrew: Participant doesn't answer phone1000
Withdrew: Participant wanted home visits1000
Withdrew: Randomized in error2000
Withdrew: No study drug on site0100
Withdrew: Stroke and stroke rehabilitation0010
Withdrew: Coagulation values cannot be set0010
Withdrew: State regulations prevent participation0010
Withdrew: Poor treatment monitoring0010
Withdrew: Participant in jail0010
Withdrew: Investigator decision0011
Withdrew: Site closure; participant won't transfer0001

Outcome measures

PrimaryThe Rate of International Society on Thrombosis and Haemostasis (ISTH) Major or Clinically Relevant Non-Major (CRNM) Bleeding With Apixaban Versus Vitamin K Antagonist (VKA) During the Treatment Period

Time to first ISTH major or CRNM bleeding during the 6-month period of treatment with Apixaban or VKA. N is the number of participants treated with Apixaban or VKA. n is the number of participants treated with Apixaban or VKA with major or CRNM bleeding in each treatment group during the 6-month period of treatment. Event rates are calculated based on the number of participants with major or CRNM bleeding divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year.

Time frame:
Approximately 6 months
Reported as:
Number · Percentage per year
The Rate of International Society on Thrombosis and Haemostasis (ISTH) Major or Clinically Relevant Non-Major (CRNM) Bleeding With Apixaban Versus Vitamin K Antagonist (VKA) During the Treatment Period
Percentage per yearApixabanVitamin K Antagonist
The Rate of International Society on Thrombosis and Haemostasis (ISTH) Major or Clinically Relevant Non-Major (CRNM) Bleeding With Apixaban Versus Vitamin K Antagonist (VKA) During the Treatment Period24.6635.79
Statistical analysis
  • Apixaban vs Vitamin K Antagonist · 1-sided p-value for NI test · p = <0.0001
  • Apixaban vs Vitamin K Antagonist · 2-sided p-value for superiority test · p = <0.0001 · Hazard ratio (hr): 0.69 · 95% CI 0.58 to 0.82
PrimaryThe Rate of ISTH Major or CRNM Bleeding With Aspirin Versus no Aspirin During the Treatment Period

Time to first ISTH major or CRNM bleeding during the treatment period of 6 months with aspirin or placebo. N is the number of participants with aspirin or placebo. n is the number of participants treated with aspirin or placebo with major or CRNM bleeding in each treatment group during the 6-month period of treatment. Event rates are calculated based on the number of participants with event of interest divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year.

Time frame:
Approximately 6 months
Reported as:
Number · Percentage per year
The Rate of ISTH Major or CRNM Bleeding With Aspirin Versus no Aspirin During the Treatment Period
Percentage per yearAcetylsalicylic Acid Film Coated TabletPlacebo Matching Acetylsalicylic Acid Film Coated Tablet
The Rate of ISTH Major or CRNM Bleeding With Aspirin Versus no Aspirin During the Treatment Period40.5121.03
Statistical analysis
  • Acetylsalicylic Acid Film Coated Tablet vs Placebo Matching Acetylsalicylic Acid Film Coated Tablet · 2-sided p-value for superiority test · p = <0.0001 · Hazard ratio (hr): 1.88 · 95% CI 1.58 to 2.23
SecondarySuperiority on ISTH Major or CRNM Bleeding for Apixaban Versus VKA

Time to first occurrence during the time the participants were treated with Apixaban or VKA. N is the number of participants treated with Apixaban or VKA. n is the number of participants treated with Apixaban or VKA with major or CRNM bleeding in each treatment group during the 6-month period of treatment. Event rates are calculated based on the number of participants with event of interest divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year.

Time frame:
Approximately 6 months
Reported as:
Number · Percentage per year
Superiority on ISTH Major or CRNM Bleeding for Apixaban Versus VKA
Percentage per yearApixabanVitamin K Antagonist
Superiority on ISTH Major or CRNM Bleeding for Apixaban Versus VKA24.6635.79
Statistical analysis
  • Apixaban vs Vitamin K Antagonist · 2-sided p-value for superiority test · p = <0.0001
SecondaryThe Rate of All-cause Death or All-cause Rehospitalization With Apixaban Versus VKA

Time to first all-cause death or all-cause hospitalization during the during the 6-month treatment period with Apixaban or VKA. N is the number of participants treated with Apixaban or VKA. n is the number of participants treated with Apixaban or VKA with all-cause death or all-cause hospitalization in each treatment group during the 6-month period of treatment. Event rates are calculated based on the number of participants with all-cause death or all-cause hospitalization divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year.

Time frame:
Approximately 6 months
Reported as:
Number · Percentage per year
The Rate of All-cause Death or All-cause Rehospitalization With Apixaban Versus VKA
Percentage per yearApixabanVitamin K Antagonist
The Rate of All-cause Death or All-cause Rehospitalization With Apixaban Versus VKA57.2469.19
Statistical analysis
  • Apixaban vs Vitamin K Antagonist · 2-sided p-value · p = 0.0033 · Hazard ratio (hr): 0.84 · 95% CI 0.75 to 0.94
SecondaryThe Rate of All-cause Death or All-cause Rehospitalization With Aspirn Versus no Aspirin

Time to first all-cause death or all-cause hospitalization during the 6-month period of treatment with aspirin or placebo. N is the number of participants treated with aspirin or placebo. n is the number of participants treated with aspirin or placebo with all-cause death or all-cause hospitalization in each treatment group during the 6-month period of treatment. Event rates are calculated based on the number of participants with all-cause death or all-cause hospitalization divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year.

Time frame:
Approximately 6 months
Reported as:
Number · Percentage per year
The Rate of All-cause Death or All-cause Rehospitalization With Aspirn Versus no Aspirin
Percentage per yearAcetylsalicylic Acid Film Coated TabletPlacebo Matching Acetylsalicylic Acid Film Coated Tablet
The Rate of All-cause Death or All-cause Rehospitalization With Aspirn Versus no Aspirin65.7260.56
Statistical analysis
  • Acetylsalicylic Acid Film Coated Tablet vs Placebo Matching Acetylsalicylic Acid Film Coated Tablet · 2-sided p-value · p = 0.2219 · Hazard ratio (hr): 1.07 · 95% CI 0.96 to 1.20
SecondaryThe Rate of the Composite Endpoint of Death or Ischemic Events (Stroke, Myocardial Infarction, Stent Thrombosis, Urgent Revascularization) With Apixaban Versus VKA

Time to first occurrence during the 6-month treatment period with Apixaban or VKA. N is the number of participants treated with Apixaban or VKA. n is the number of participants treated with Apixaban or VKA with death or ischemic events in each treatment group during the during the 6-month period of treatment. Event rates are calculated based on the number of participants with death or ischemic events divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year.

Time frame:
Approximately 6 months
Reported as:
Number · Percentage per year
The Rate of the Composite Endpoint of Death or Ischemic Events (Stroke, Myocardial Infarction, Stent Thrombosis, Urgent Revascularization) With Apixaban Versus VKA
Percentage per yearApixabanVitamin K Antagonist
The Rate of the Composite Endpoint of Death or Ischemic Events (Stroke, Myocardial Infarction, Stent Thrombosis, Urgent Revascularization) With Apixaban Versus VKA15.8517.17
Statistical analysis
  • Apixaban vs Vitamin K Antagonist · 2-sided p-value · p = 0.4370 · Hazard ratio (hr): 0.92 · 95% CI 0.75 to 1.13
SecondaryThe Composite Endpoints of Death and Ischemic Events (Stroke, Myocardial Infarction, Stent Thrombosis, Urgent Revascularization) With Aspirin Versus no Aspirin

Time to first death or ischenic event during the 6-month treatment period with aspirin or placebo. N is the number of participants treated with aspirin or placebo. n is the number of participants treated with aspirin or placebo with death or ischemic events in each treatment group during the 6-month treatment period. Event rates are calculated based on the number of participants with death or ischemic events divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year.

Time frame:
Approximately 6 months
Reported as:
Number · Percentage per year
The Composite Endpoints of Death and Ischemic Events (Stroke, Myocardial Infarction, Stent Thrombosis, Urgent Revascularization) With Aspirin Versus no Aspirin
Percentage per yearAcetylsalicylic Acid Film Coated TabletPlacebo Matching Acetylsalicylic Acid Film Coated Tablet
The Composite Endpoints of Death and Ischemic Events (Stroke, Myocardial Infarction, Stent Thrombosis, Urgent Revascularization) With Aspirin Versus no Aspirin15.2817.73
Statistical analysis
  • Acetylsalicylic Acid Film Coated Tablet vs Placebo Matching Acetylsalicylic Acid Film Coated Tablet · 2-sided p-value · p = 0.1742 · Hazard ratio (hr): 0.86 · 95% CI 0.70 to 1.07

Adverse events

Collected over Includes adverse events (AEs) with onset on or after the first dose of study medication through 2 days (for non-serious AE) or 30 days (for serious AE) after the last dose of study medication (approximately 7 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Apixaban With Acetylsalicylic Acid Film Coated Tablet42/1,145 (3.7%)53/1,145 (4.6%)35/1,145 (3.1%)
Apixaban With Placebo Matching Acetylsalicylic Acid46/1,143 (4%)50/1,143 (4.4%)21/1,143 (1.8%)
Vitamin K Antagonist (VKA) With Acetylsalicylic Acid38/1,123 (3.4%)52/1,123 (4.6%)33/1,123 (2.9%)
VKA With Placebo Matching Acetylsalicylic Acid42/1,127 (3.7%)55/1,126 (4.9%)18/1,126 (1.6%)
APIXABAN ONLY0/2 (0%)0/2 (0%)0/2 (0%)
VKA ONLY3/10 (30%)3/10 (30%)1/10 (10%)
ACETYLSALICLIC ACID ONLY0/9 (0%)0/9 (0%)3/9 (33.3%)
PLACEBO MATCHING ACETYLSALICLIC ACID ONLY0/10 (0%)0/10 (0%)0/10 (0%)
Most frequent serious events
Showing 10 of 84
Most frequent serious events
EventApixaban With Acetylsalicylic Acid Film Coated TabletApixaban With Placebo Matching Acetylsalicylic AcidVitamin K Antagonist (VKA) With Acetylsalicylic AcidVKA With Placebo Matching Acetylsalicylic AcidAPIXABAN ONLYVKA ONLYACETYLSALICLIC ACID ONLYPLACEBO MATCHING ACETYLSALICLIC ACID ONLY
Cardiac failureCardiac disorders1/11459/11435/11233/11260/21/100/90/10
Cerebral haemorrhageNervous system disorders0/11450/11430/11232/11260/21/100/90/10
Peripheral ischaemiaVascular disorders1/11450/11430/11230/11260/21/100/90/10
Acute myocardial infarctionCardiac disorders3/11451/11436/11233/11260/20/100/90/10
Myocardial infarctionCardiac disorders4/11455/11435/11232/11260/20/100/90/10
OverdoseInjury, poisoning and procedural complications2/11450/11435/11231/11260/20/100/90/10
Sudden deathGeneral disorders5/11453/11432/11231/11260/20/100/90/10
Accidental overdoseInjury, poisoning and procedural complications1/11451/11431/11234/11260/20/100/90/10
Cardiac arrestCardiac disorders2/11453/11433/11233/11260/20/100/90/10
Ischaemic strokeNervous system disorders0/11450/11433/11230/11260/20/100/90/10
Most frequent other events
Most frequent other events
EventApixaban With Acetylsalicylic Acid Film Coated TabletApixaban With Placebo Matching Acetylsalicylic AcidVitamin K Antagonist (VKA) With Acetylsalicylic AcidVKA With Placebo Matching Acetylsalicylic AcidAPIXABAN ONLYVKA ONLYACETYLSALICLIC ACID ONLYPLACEBO MATCHING ACETYLSALICLIC ACID ONLY
AnaemiaBlood and lymphatic system disorders16/11453/114310/11236/11260/20/101/90/10
Cardiac failureCardiac disorders8/11458/11439/11235/11260/20/101/90/10
Puncture site reactionGeneral disorders0/11450/11430/11230/11260/20/101/90/10
PneumoniaInfections and infestations5/11451/11432/11232/11260/20/101/90/10
Vascular pseudoaneurysmInjury, poisoning and procedural complications0/11450/11431/11230/11260/20/101/90/10
Acute kidney injuryRenal and urinary disorders9/11453/11435/11232/11260/20/101/90/10
HaematomaVascular disorders4/11453/11436/11231/11260/20/101/90/10
HaematuriaRenal and urinary disorders2/11453/11435/11233/11260/21/100/90/10

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Apixaban With Acetylsalicylic Acid Film Coated TabletApixaban With Placebo Matching Acetylsalicylic AcidVitamin K Antagonist (VKA) With AcetylsalicylicVKA With Placebo Matching Acetylsalicylic AcidTotal
Mean70.2 ± 9.1269.3 ± 9.3270.0 ± 9.0970.0 ± 9.1369.9 ± 9.17
Age, Customized
Age, Customized(Participants)Apixaban With Acetylsalicylic Acid Film Coated TabletApixaban With Placebo Matching Acetylsalicylic AcidVitamin K Antagonist (VKA) With AcetylsalicylicVKA With Placebo Matching Acetylsalicylic AcidTotal
< 65 years old3083333113151267
65-80 years old6646606626572643
>=80181160181182704
Sex: Female, Male
Sex: Female, Male(Participants)Apixaban With Acetylsalicylic Acid Film Coated TabletApixaban With Placebo Matching Acetylsalicylic AcidVitamin K Antagonist (VKA) With AcetylsalicylicVKA With Placebo Matching Acetylsalicylic AcidTotal
Female3573133393281337
Male7968408158263277
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Apixaban With Acetylsalicylic Acid Film Coated TabletApixaban With Placebo Matching Acetylsalicylic AcidVitamin K Antagonist (VKA) With AcetylsalicylicVKA With Placebo Matching Acetylsalicylic AcidTotal
Hispanic or Latino2107524
Not Hispanic or Latino114123120126483
Unknown or Not Reported10371020102710234107
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Apixaban With Acetylsalicylic Acid Film Coated TabletApixaban With Placebo Matching Acetylsalicylic AcidVitamin K Antagonist (VKA) With AcetylsalicylicVKA With Placebo Matching Acetylsalicylic AcidTotal
White10391058104310444184
Black/African American1712121859
Asian35353931140
American Indian/Alaska Native462416
Native Hawaiian/Other Pacific Islander00011
Other47293843157
Not Reported1113201357
08

Study locations

626 sites
  • Cardiovascular Associates of the Southeast, LLC
    Birmingham, Alabama 35243, United States
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294-3410, United States
  • Arizona Heart Rhythm Center
    Phoenix, Arizona 85013, United States
  • Local Institution
    Phoenix, Arizona 85054, United States
  • Scottsdale Osborn Medical Center
    Scottsdale, Arizona 85251, United States
  • Southern Arizona VA Health Care System
    Tucson, Arizona 85723, United States
  • Local Institution
    Little Rock, Arkansas 72204, United States
  • Local Institution
    Phoenix, Arkansas 85015, United States
  • Comprehensive Cardiovascular Specialists
    Alhambra, California 91801, United States
  • Local Institution
    Culver City, California 90230, United States
  • Washington Township Medical Foundation
    Fremont, California 94536, United States
  • California Heart Specialist, Inc.
    Huntington Beach, California 92648, United States
  • Foundation For Cardiovascular Medicine
    La Jolla, California 92037, United States
  • Local Institution
    Long Beach, California 90806, United States
  • Local Institution
    Rancho Mirage, California 92270, United States
  • Local Institution
    San Diego, California 92161, United States
  • Manshadi Heart Institute
    Stockton, California 95204, United States
  • Local Institution
    Torrance, California 90502, United States
  • University Of Colorado
    Aurora, Colorado 80045, United States
  • Colorado Heart and Vascular
    Lakewood, Colorado 80228, United States
  • Local Institution
    Norwalk, Connecticut 06851, United States
  • Local Institution
    Wilmington, Delaware 19803, United States
  • Orlando Heart Specialists
    Altamonte Springs, Florida 32714, United States
  • Local Institution
    Bradenton, Florida 34209, United States
  • Clearwater Cardiovascular and Interventional Consultants
    Clearwater, Florida 33756, United States
  • Local Institution
    Clearwater, Florida 33756, United States
  • Daytona Heart Group
    Daytona Beach, Florida 32114, United States
  • Local Institution
    Fort Lauderdale, Florida 33316, United States
  • Local Institution
    Jacksonville Beach, Florida 32250, United States
  • Local Institution
    Jacksonville, Florida 32204, United States
  • Local Institution
    Jacksonville, Florida 32216, United States
  • Tenet Florida Physician Services
    Jupiter, Florida 33458, United States
  • Local Institution
    Lake Mary, Florida 32746, United States
  • Local Institution
    Miami, Florida 33173, United States
  • Mediquest Research
    Ocala, Florida 34471, United States
  • Local Institution
    Orlando, Florida 32825, United States
  • CP Cardiology Partners
    Palm Beach Gardens, Florida 33410, United States
  • Bayfront Health St. Petersburg
    Saint Petersburg, Florida 33701, United States
  • Local Institution
    Tampa, Florida 33613, United States
  • Cardiology Partners
    Wellington, Florida 33449, United States
  • Athens Regional Cariology Group
    Athens, Georgia 30606, United States
  • Local Institution
    Atlanta, Georgia 30342, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Georgia Heart Specialists
    Covington, Georgia 30014, United States
  • Local Institution
    Cumming, Georgia 30041, United States
  • Local Institution
    Tucker, Georgia 30084, United States
  • Saint Lukes Idaho Cardiology Associates
    Boise, Idaho 83712, United States
  • Medicoricium, LLC
    Fairview Heights, Illinois 62208, United States
  • Gateway Cardiology PC
    Jerseyville, Illinois 62052, United States
  • Advocate Medical Group ? Cardiology and Pulmonology
    Normal, Illinois 61761, United States
  • South Suburban Cardiology
    Olympia Fields, Illinois 60461, United States
  • Local Institution
    Bloomington, Indiana 47403, United States
  • Elkhart Clinic LLC
    Elkhart, Indiana 46514, United States
  • Roudebush VA Medical Center
    Indianapolis, Indiana 46202, United States
  • Reid Hospital and Health Care Services
    Richmond, Indiana 47374, United States
  • Midwest Cardiovascular Research Foundation
    Davenport, Iowa 52803, United States
  • University of Iowa Stead Family Children's Hospital
    Iowa City, Iowa 52242, United States
  • Northeast Iowa Family Practice Center
    Waterloo, Iowa 50702, United States
  • Local Institution
    Kansas City, Kansas 66160, United States
  • Local Institution
    Wichita, Kansas 67203, United States
  • Saint Elizabeth Healthcare
    Crestview Hills, Kentucky 41017, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Alexandria Cardiology Clinic
    Alexandria, Louisiana 71301, United States
  • Imperial Health
    Lake Charles, Louisiana 70601, United States
  • Local Institution
    Minden, Louisiana 71055, United States
  • Clinical Trials of America LA LLC - PPDS
    Monroe, Louisiana 71201, United States
  • Local Institution
    Natick, Massachusetts 01760, United States
  • Great Lakes Heart Center of Alpena
    Alpena, Michigan 49707, United States
  • Local Institution
    Ann Arbor, Michigan 48109, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Local Institution
    Detroit, Michigan 48202, United States
  • Local Institution
    Lansing, Michigan 48912, United States
  • Covenant Center for the Heart
    Saginaw, Michigan 48602, United States
  • Metropolitan Cardiology Consultants
    Minneapolis, Minnesota 55433-4568, United States
  • Hattiesburg Clinic
    Hattiesburg, Mississippi 39401, United States
  • Local Institution
    Jackson, Mississippi 39216, United States
  • Cardiology Associates Research LLC
    Tupelo, Mississippi 38801, United States
  • Missouri Cardiovascular Specialists
    Columbia, Missouri 65201, United States
  • Local Institution
    Columbia, Missouri 65212, United States
  • Freeman Health System
    Joplin, Missouri 64804, United States
  • Gateway Cardiology PC
    Saint Louis, Missouri 63128, United States
  • St. Louis Heart and Vascular
    Saint Louis, Missouri 63136, United States
  • Cox Health Systems
    Springfield, Missouri 65807, United States
  • Local Institution
    Billings, Montana 59101, United States
  • Bryan Heart Hospital
    Lincoln, Nebraska 68506, United States
  • HCP Clinical Research LLC
    Las Vegas, Nevada 89169, United States
  • Renown Regional Medical Center.
    Reno, Nevada 89502, United States
  • New Jersey Heart
    Linden, New Jersey 07036, United States
  • Capital Cardiology Associates
    Albany, New York 12211, United States
  • New York-Presbyterian Brooklyn Methodist Hospital
    Brooklyn, New York 11215, United States
  • Local Institution
    Brooklyn, New York 11217, United States
  • Buffalo Heart Group LLP
    Buffalo, New York 14215, United States
  • Mount Sinai-St. Lukes
    New York, New York 10025, United States
  • Hudson Valley Cardiovascular Practice, PC
    Poughkeepsie, New York 12601, United States
  • Asheville Cardiology Associates PA
    Asheville, North Carolina 28801, United States
  • University of North Carolina School of Medicine
    Chapel Hill, North Carolina 27599, United States
  • Durham VA Medical Center
    Durham, North Carolina 27705, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Clinical Trials of America-NC, LLC - PPDS
    Lenoir, North Carolina 28645, United States
  • Duke Cardiology and Cardiovascular Surgery of Lumberton
    Lumberton, North Carolina 28358, United States

Showing the first 100 of 626 sites across 37 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bahit MC, Vora AN, Li Z, Wojdyla DM, Thomas L, Goodman SG, Aronson R, Jordan JD, Kolls BJ, Dombrowski KE, Vinereanu D, Halvorsen S, Berwanger O, Windecker S, Mehran R, Granger CB, Alexander JH, Lopes RD. Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial. JAMA Cardiol. 2022 Jul 1;7(7):682-689. doi: 10.1001/jamacardio.2022.1166. PubMed 35612866 ↗
  • Welsh RC, Dehghani P, Lopes R, Wojdyla DM, Aronson R, Granger CB, Windecker S, Vora AN, Vinereanu D, Halvorsen S, Parkhomenko A, Mehran R, Alexander JH, Goodman S. Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial. Open Heart. 2022 Feb;9(1):e001892. doi: 10.1136/openhrt-2021-001892. PubMed 35172988 ↗
  • Harskamp RE, Fanaroff AC, Lopes RD, Wojdyla DM, Goodman SG, Thomas LE, Aronson R, Windecker S, Mehran R, Granger CB, Alexander JH. Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention. J Am Coll Cardiol. 2022 Feb 8;79(5):417-427. doi: 10.1016/j.jacc.2021.11.035. PubMed 35115097 ↗
  • Hijazi Z, Alexander JH, Li Z, Wojdyla DM, Mehran R, Granger CB, Parkhomenko A, Bahit MC, Windecker S, Aronson R, Berwanger O, Halvorsen S, de Waha-Thiele S, Sinnaeve P, Darius H, Storey RF, Lopes RD. Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. Circulation. 2021 Mar 23;143(12):1215-1223. doi: 10.1161/CIRCULATIONAHA.120.051020. Epub 2021 Jan 19. PubMed 33461308 ↗
  • Alexander JH, Wojdyla D, Vora AN, Thomas L, Granger CB, Goodman SG, Aronson R, Windecker S, Mehran R, Lopes RD. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS. Circulation. 2020 May 19;141(20):1618-1627. doi: 10.1161/CIRCULATIONAHA.120.046534. Epub 2020 Mar 29. PubMed 32223444 ↗
  • Lopes RD, Leonardi S, Wojdyla DM, Vora AN, Thomas L, Storey RF, Vinereanu D, Granger CB, Goodman SG, Aronson R, Windecker S, Thiele H, Valgimigli M, Mehran R, Alexander JH. Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. Circulation. 2020 Mar 3;141(9):781-783. doi: 10.1161/CIRCULATIONAHA.119.044584. Epub 2019 Nov 11. No abstract available. PubMed 31707833 ↗
  • Windecker S, Lopes RD, Massaro T, Jones-Burton C, Granger CB, Aronson R, Heizer G, Goodman SG, Darius H, Jones WS, Aschermann M, Brieger D, Cura F, Engstrom T, Fridrich V, Halvorsen S, Huber K, Kang HJ, Leiva-Pons JL, Lewis BS, Malaga G, Meneveau N, Merkely B, Milicic D, Morais J, Potpara TS, Raev D, Sabate M, de Waha-Thiele S, Welsh RC, Xavier D, Mehran R, Alexander JH; AUGUSTUS Investigators. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. Circulation. 2019 Dec 3;140(23):1921-1932. doi: 10.1161/CIRCULATIONAHA.119.043308. Epub 2019 Sep 26. PubMed 31557056 ↗
  • Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, Goodman SG, Windecker S, Darius H, Li J, Averkov O, Bahit MC, Berwanger O, Budaj A, Hijazi Z, Parkhomenko A, Sinnaeve P, Storey RF, Thiele H, Vinereanu D, Granger CB, Alexander JH; AUGUSTUS Investigators. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019 Apr 18;380(16):1509-1524. doi: 10.1056/NEJMoa1817083. Epub 2019 Mar 17. PubMed 30883055 ↗
  • Lopes RD, Vora AN, Liaw D, Granger CB, Darius H, Goodman SG, Mehran R, Windecker S, Alexander JH. An open-Label, 2 x 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. Am Heart J. 2018 Jun;200:17-23. doi: 10.1016/j.ahj.2018.03.001. Epub 2018 Mar 9. PubMed 29898844 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Nov 2018, 41 months.

Results were first posted in Feb 2020, 1 year 2 months after primary completion.

Of 92 phase 4 interventional studies under Acute Coronary Syndrome, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's 41 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2015
First posted
Apr 14, 2015
StartActual
Jun 4, 2015
Primary completionActual
Nov 10, 2018
CompletionActual
Nov 10, 2018
Results first posted
Feb 7, 2020
Last update
Jun 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02415400
Collaborators
Pfizer, Duke Clinical Research Institute
Responsible party
Sponsor
First posted
Apr 14, 2015
Start date
Jun 4, 2015
Primary completion
Nov 10, 2018
Completion
Nov 10, 2018
Results posted
Feb 7, 2020
Last update
Jun 11, 2020

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Apixaban · Vitamin K Antagonist

Start the discussion